Can I Take Omega-3 (EPA/DHA) with Jardiance (Empagliflozin)?

What Is the Interaction Between Omega-3 and Jardiance?

The combination produces a pharmacodynamic interaction, not a pharmacokinetic one. Empagliflozin is metabolized primarily by UGT2B7 and UGT1A3 glucuronidation with minimal CYP450 involvement, so omega-3 fatty acids, which are not CYP inducers or inhibitors at any dietary or prescription dose, do not alter empagliflozin plasma concentrations [1][2]. The two agents do not compete for the same transport proteins or renal excretion pathways.

The pharmacodynamic concern centers on antiplatelet activity. Omega-3 fatty acids reduce thromboxane A2 synthesis in platelets, modestly prolonging bleeding time [3]. Empagliflozin and other SGLT2 inhibitors have demonstrated platelet-inhibitory effects in preclinical and small clinical work, attributed in part to reduced oxidative stress and improved endothelial function [4]. Taken together, the combination may produce slightly more platelet inhibition than either agent alone, though the clinical significance of this effect in the absence of a third antiplatelet or anticoagulant drug appears low.

Pharmacokinetic Profile of Empagliflozin

Empagliflozin reaches peak plasma concentration (Cmax) approximately 1.5 hours after oral dosing, with a bioavailability of roughly 84% [1]. Food, including a high-fat meal, reduces Cmax by 37% but does not affect overall area under the curve (AUC), which means taking the tablet with a fish-oil-containing meal is acceptable [1]. Renal excretion accounts for approximately 54% of an oral dose, predominantly as glucuronide conjugates [1].

Pharmacokinetic Profile of Omega-3 Fatty Acids

EPA and DHA are incorporated into chylomicrons after intestinal absorption and are subsequently distributed to plasma phospholipids and tissues [3]. They are not substrates or inhibitors of CYP1A2, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 at doses up to 4 g/day [5]. The FDA-approved formulation icosapentaenoic acid ethyl ester (Vascepa, 4 g/day) demonstrated no clinically significant drug interactions in formal pharmacokinetic studies [5].

How Does Each Drug Affect Cardiovascular Risk Separately?

Empagliflozin and Heart Outcomes

The EMPA-REG OUTCOME trial (N=7,020 adults with type 2 diabetes and established cardiovascular disease) showed that empagliflozin 10 mg or 25 mg daily reduced the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke by 14% versus placebo (hazard ratio 0.86; 95% CI 0.74-0.99; P<0.001 for noninferiority, P=0.04 for superiority) [6]. Cardiovascular mortality alone fell by 38%. The trial ran 3.1 years at a median follow-up.

Empagliflozin also reduced hospitalization for heart failure by 35% in EMPA-REG OUTCOME [6]. The EMPEROR-Reduced trial (N=3,730) extended this benefit to patients with heart failure with reduced ejection fraction regardless of diabetes status, cutting the composite of CV death or HF hospitalization by 25% over a median of 16 months [7].

Omega-3 and Cardiovascular Outcomes

The REDUCE-IT trial (N=8,179) tested icosapentaenoic acid (icosapentaenoic acid ethyl ester, 4 g/day) in statin-treated patients with elevated triglycerides (135-499 mg/dL) and established cardiovascular disease or diabetes plus a risk factor. At a median follow-up of 4.9 years, icosapentaenoic acid reduced the primary composite endpoint of cardiovascular death, nonfatal MI, nonfatal stroke, coronary revascularization, or unstable angina by 25% versus mineral oil placebo (HR 0.75; 95% CI 0.68-0.83; P<0.001) [8]. Cardiovascular death alone fell by 20%.

The STRENGTH trial (N=13,078) tested a mixed EPA+DHA formulation at 4 g/day against corn oil and found no significant reduction in major adverse cardiovascular events [9]. This divergence between trials has led many cardiologists to regard pure EPA formulations as more effective than blended EPA/DHA products for CV event reduction, though the debate is ongoing [9].

Can the Combination Produce Additive Cardiovascular Benefit?

Given that the two agents act through entirely different mechanisms, additive CV benefit is biologically plausible. Empagliflozin improves cardiac preload and afterload by promoting natriuresis, reducing plasma volume, and lowering arterial stiffness [6][7]. Omega-3 fatty acids lower triglycerides, reduce inflammation via resolvins and protectins, and modulate membrane ion channel activity in cardiomyocytes [3][8].

No dedicated randomized controlled trial has tested the combination head-to-head against either monotherapy for CV outcomes. Observational data suggest the combination is common in clinical practice among patients with type 2 diabetes and hypertriglyceridemia. Both the American Diabetes Association Standards of Care in Diabetes 2024 [10] and the 2021 ACC/AHA cardiovascular risk guideline [11] recommend SGLT2 inhibitors in patients with T2D and established CV disease or high CV risk; icosapentaenoic acid is a Class IIa recommendation for patients on statins with residual triglycerides above 135 mg/dL [11].

A Practical Decision Framework for the Combination

The following framework guides when to add omega-3 to an existing empagliflozin regimen:

1. Fasting triglycerides 135-499 mg/dL despite statin therapy. Consider prescription icosapentaenoic acid 4 g/day per ACC/AHA Class IIa guidance [11].
2. Fasting triglycerides <135 mg/dL, no established CVD. Over-the-counter fish oil at dietary supplement doses (1-2 g EPA+DHA/day) may be taken; dedicated CV event-reduction evidence is weaker at these doses.
3. Patient on anticoagulation (warfarin, apixaban, rivaroxaban) or dual antiplatelet therapy. Obtain a bleeding risk assessment before adding omega-3 at prescription doses; consult the prescribing cardiologist.
4. Bleeding history or platelet count <100,000/mcL. Start at the lowest omega-3 dose and monitor for bruising or prolonged wound bleeding.

What Is the Bleeding Risk When Combining These Agents?

Antiplatelet Mechanism of Omega-3

EPA and DHA compete with arachidonic acid for cyclooxygenase-1 (COX-1), reducing thromboxane A2 production and therefore platelet aggregation. In a meta-analysis of 17 randomized trials (N=1,514) published in the Journal of Nutrition, fish oil at 3-6 g/day prolonged bleeding time by a mean of 0.42 minutes versus control [3]. This effect is pharmacologically real but clinically small in the absence of other hemostatic insults.

Antiplatelet Activity of SGLT2 Inhibitors

Pre-clinical data from human platelet studies have shown empagliflozin reduces ADP-induced and collagen-induced platelet aggregation in vitro, potentially through a reduction in reactive oxygen species inside the platelet [4]. A 2022 observational analysis in patients with type 2 diabetes found that SGLT2 inhibitor use was associated with a lower incidence of venous thromboembolism compared with DPP-4 inhibitors, suggesting a mild antithrombotic signal in vivo [4].

Putting the Risk in Context

Major bleeding events attributable to the fish oil plus empagliflozin combination alone have not been reported in the published literature. Risk becomes more relevant when aspirin, a P2Y12 inhibitor (clopidogrel, ticagrelor), or an anticoagulant is co-prescribed. In that scenario, a clinician review of the full medication list is warranted before initiating prescription-dose omega-3 therapy.

Does Omega-3 Affect Blood Glucose or the Efficacy of Empagliflozin?

Early meta-analyses raised concerns that omega-3 supplementation could worsen glycemic control in type 2 diabetes. A 2012 Cochrane review (36 trials, N=2,795) found omega-3 supplementation had no clinically significant effect on HbA1c (mean difference 0.03%; 95% CI -0.09% to 0.16%; P<0.001 for heterogeneity), fasting glucose, or insulin resistance [12]. Doses ranged from 0.9 g to 6.6 g EPA+DHA per day.

Empagliflozin lowers HbA1c by approximately 0.5-0.7% versus placebo at 10-25 mg daily in phase 3 trials [1]. Omega-3 co-administration does not appear to blunt this glucose-lowering effect. No mechanistic interaction has been identified at SGLT2 transporter level [1][2].

Effect on Lipids: Does the Combination Produce Additive Triglyceride Lowering?

Empagliflozin and Lipids

Empagliflozin produces modest but consistent reductions in triglycerides. A pooled analysis of four phase 3 trials (N=2,477) showed mean triglyceride reduction of 9.8 mg/dL versus placebo at 24 weeks [1]. LDL-cholesterol may increase slightly (approximately 2-3 mg/dL), an effect attributed to shifts in lipoprotein composition rather than absolute LDL particle number [1].

Prescription Omega-3 and Lipids

At 4 g/day, icosapentaenoic acid (Vascepa) reduced triglycerides by 21.5% from baseline in REDUCE-IT (median baseline 216 mg/dL) [8]. The blended EPA+DHA product omega-3-acid ethyl esters (Lovaza) produces a ~30% triglyceride reduction at 4 g/day but raises LDL-C by approximately 45% in some patients with very high baseline triglycerides [5]. Over-the-counter fish oil at 1-2 g/day typically reduces triglycerides by 5-10% [3].

Combining empagliflozin with prescription-strength omega-3 may therefore produce additive triglyceride lowering of 25-35% in patients with elevated baseline triglycerides, though a controlled head-to-head study quantifying this combination specifically has not been published.

LDL Monitoring Consideration

Because omega-3-acid ethyl esters (Lovaza) can raise LDL-C while empagliflozin also produces a mild LDL shift, a fasting lipid panel 8-12 weeks after initiating combination therapy is reasonable [5][10].

Does Empagliflozin Interact with Any Other Common Supplements?

Empagliflozin carries documented cautions with agents that lower blood pressure (additive hypotension), diuretics (additive volume depletion), and insulin or sulfonylureas (additive hypoglycemia risk) [1]. Among dietary supplements, berberine deserves attention because it activates AMPK and may produce additive glucose lowering; the combination has not been formally studied in randomized trials but case reports of hypoglycemia exist [13].

Magnesium supplementation is common in people with type 2 diabetes given the high prevalence of hypomagnesemia in this population; no interaction with empagliflozin has been identified [14]. Chromium picolinate and alpha-lipoic acid also lack documented pharmacokinetic interactions with empagliflozin, though both have weak glucose-lowering activity that could theoretically augment hypoglycemia risk when insulin is co-prescribed [13].

Monitoring Recommendations for Patients Taking Both Agents

Patients combining empagliflozin with omega-3 should receive the following monitoring, consistent with ADA Standards of Care 2024 [10] and FDA prescribing information for each agent [1][5]:

• HbA1c every 3 months until at goal, then every 6 months
• Fasting lipid panel at baseline, 8-12 weeks after adding or changing omega-3 dose, then annually
• eGFR and serum creatinine every 6-12 months; empagliflozin should be paused if eGFR falls below 20 mL/min/1.73 m2 [1]
• Urine albumin-to-creatinine ratio annually to monitor renal protection
• Blood pressure at each visit; empagliflozin lowers systolic BP by 3-5 mmHg and the combination with omega-3 may add a small further reduction via improved endothelial function [6]
• Signs of bleeding such as unexplained bruising, prolonged bleeding from minor cuts, or blood in urine/stool, especially in patients on concomitant antiplatelet or anticoagulant therapy [3][4]

Practical Dosing and Timing Guidance

No dose separation is required. Empagliflozin is typically taken once daily in the morning with or without food [1]. Omega-3 supplements or prescription capsules can be taken at the same time, with a meal, to improve tolerance and reduce the fish-oil aftertaste. Taking both with breakfast is a practical approach that also aligns omega-3 absorption with dietary fat intake, which enhances EPA/DHA bioavailability by approximately 50% compared with a fasted state [5].

Over-the-counter fish oil products vary substantially in actual EPA+DHA content. A label claiming "1,000 mg fish oil" may deliver only 300 mg combined EPA+DHA. Patients aiming for the evidence-based triglyceride-lowering dose of 2-4 g/day EPA+DHA should use products with third-party certification (NSF International, USP, or IFOS) or request a prescription formulation [5][8].

Who Should Discuss This Combination with Their Prescriber First?

Most adults with type 2 diabetes, heart failure, or CKD taking empagliflozin can add dietary-dose omega-3 (up to approximately 2 g EPA+DHA/day) without specific medical clearance beyond standard medication review. The following groups benefit from a prescriber conversation before starting prescription-dose omega-3 (4 g/day):

• Patients on warfarin, apixaban, rivaroxaban, dabigatran, or edoxaban
• Patients on dual antiplatelet therapy (aspirin plus a P2Y12 inhibitor)
• Patients with a personal or family history of bleeding disorders
• Patients with atrial fibrillation on rhythm-control therapy, given omega-3 at high doses has shown a signal for new or recurrent AF in some trials [8][9]
• Patients with planned surgery within 2 weeks; most guidelines recommend pausing omega-3 at 4 g/day 5-7 days before elective procedures [11]

The ADA Standards of Care 2024 state: "Omega-3 fatty acid supplements are not recommended to reduce cardiovascular risk, though prescription icosapentaenoic acid may be considered in patients with elevated triglycerides already treated with a statin to reduce cardiovascular risk." [10]